A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34308518/

The results of this real-world study suggest that treatment outcomes with CDK4/6 inhibitors may be worse in patients with gBRCAm mBC than in their counterparts with gBRCAwt and unknown gBRCA...

Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34315723/

Tumor-specific MHC-II has strong candidacy as a specific biomarker of anti-PD-1/L1 immunotherapy benefit when added to standard NAC in HER2-negative breast cancer. Combined with previous studies in melanoma, MHCII has...

Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34258343/

doi: 10.1016/j.jdcr.2021.05.028. 1 Georgetown University School of Medicine, Washington, District of Columbia. 2 Department of Dermatology, MedStar Washington Hospital Center/Georgetown University Hospital, Washington, District of Columbia. Free PMC article Free...

Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34271137/

The formation of cyclinD-CDK4/6 complex plays vital roles in the cell cycle transition from G1 phase to S phase which is characterized by vigorous transcription and synthesis. Through cyclinD-CDK4/6-Rb axis,...

Higher-risk breast cancer in women aged 80 and older: Exploring the effect of treatment on survival - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34274566/

doi: 10.1016/j.breast.2021.07.005. Online ahead of print. 1 Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Tom Baker Cancer Centre, Calgary, Alberta, Canada.